Ê×Ò½ÉúÀíѧ£¨2006-2016£©
Ãû´Ê½âÊÍ£º
1¡¢ sodium-potassium pump (2016)
ÓÉαºÍβÁ½¸öÑǵ¥Î»×é³ÉµÄ¶þ¾ÛÌåµ°°×ÖÊ£¬¾ßÓÐATPøµÄ»îÐÔ¡£µ±Ï¸°ûÄÚNa+Ũ¶ÈÉý¸ßʱ£¬ÄƱñ»¼¤»î£¬Ê¹ATP·Ö½âΪADP£¬ÊͷŵÄÄÜÁ¿ÓÃÓÚNa+ºÍK+µÄÖ÷¶¯×ªÔË¡£1·Ö×ÓATP·Ö½âÊͷŵÄÄÜÁ¿¿ÉÒÔ½«3¸öNa+Ô˵½Ï¸°ûÍ⣬¶ø½«2¸öK+ÔËÈëϸ°ûÄÚ£¬¹ÊÄÆ±ÃÒ²³ÆÎªNa+-k+ÒÀÒÀÀµÊ½ATPø¡£
2¡¢ heterometric regulation (2016)
¼´ÐÄÔàǰ¸ººÉ(Ðõ³¤¶È)¶Ô²«³öÁ¿µÄÓ°Ï죬ÐÄÔàǰ¸ººÉÊÇÖ¸ÐÄÊÒÊÕËõǰËù³ÐÊܵĸººÉ¡£Í¨³£ÓÃÐÄÊÒÊæÕÅÄ©ÆÚѹÁ¦»òÐÄÊÒÊæÕÅÄ©ÆÚÈÝ»ýÀ´·´Ó¦¡£²«³öÁ¿Óëǰ¸ººÉÓйأ¬ÔÚÒ»¶¨ÏÞ¶ÈÄÚǰ¸ººÉÔö¼Ó→²«³öÁ¿Ôö¼Ó¡£
3¡¢ receptor potential (2016)
µ±´Ì¼¤×÷ÓÃÓÚ¸ÐÊÜÆ÷ʱ£¬ÔÚ¸ÐÊÜÆ÷ϸ°ûÄÚ»ò¸Ð¾õÉñ¾Ä©ÉÒÒýÆðµÄµçλ±ä»¯¡£ËüÊÇÒ»ÖÖ¹ý¶É ÐÔÂýµç룬¾ßÓоֲ¿µçλµÄÌØÕ÷¡£
4¡¢ Secondary active transport (2015)
ÊÇÎïÖÊ¿çĤתÔË·½Ê½µÄÒ»ÖÖ£¬µ±Ä³ÖÖÎïÖÊÄܹ»ÄæÅ¨¶È²î½øÐпçĤÔËÊ䣬µ«ÊÇÆäÄÜÁ¿²»ÊÇÀ´×ÔÓÚATP·Ö½â£¬¶øÊÇÓÉÖ÷¶¯×ªÔËÆäËûÎïÖÊʱÔì³ÉµÄ¸ßÊÆÄÜÌṩ£¬ÕâÖÖתÔË·½Ê½³ÆÎª¼Ì·¢ÐÔÖ÷¶¯×ªÔË¡£
5¡¢ Hemostasis (2014)
СѪ¹ÜÆÆËðºó£¬ÑªÒº½«´ÓѪ¹ÜÁ÷³ö£¬¼¸·ÖÖÓÄÚ»á×ÔÐÐÍ£Ö¹£¬ÕâÖÖÏÖÏó³ÆÎªÉúÀíÐÔֹѪ¡£ÉúÀíÐÔֹѪ¹ý³Ì°üÀ¨ÊÜËðµÄСѪ¹ÜÊÕËõ¡¢ÑªÐ¡°åֹѪ˨ ÐγɺÍѪҺÄý¹ÌÈý¸ö¹ý³Ì¡£
6¡¢ postsynaptic facilitation (2014)
ÓÉÓÚÍ»´¥ºóĤµÄÈ¥¼«»¯£¬Ê¹Ä¤µç λ¿¿½üãеç룬ÔÚ´Ë»ù´¡ÉϵÄÒ»´Î¶îÍâ´Ì¼¤£¬±È½ÏÈÝÒ×´ïµ½ãеç λ¶ø±¬·¢¶¯×÷µçλ¡£
7¡¢ supernormal period (2013)
³¬³£ÆÚÊÇÖ¸¸øÉñ¾ÒÔµ¥Ò»´Ì¼¤Ê¹Ö®ÐË·Üʱ£¬ÓÐÒ»¶Ìʱ¼äµÄ²»Ó¦ÆÚ£¬´Ëºó³öÏÖµÄÒ»¹ýÐÔµÄÐË·ÜÐÔ³¬¹ýÕý³£ÖµµÄʱÆÚ¡£
8¡¢ negative after potential (2013)
·æµçλ¹ýºó¼´ÎªÀúʱ½Ï³¤µÄºóµçλ£ºÏÈΪ¸ººóµç룬ÀúʱԼ5-30ºÁÃ룬Æä·ù¶ÈԼΪ·æµçλµÄ5¡«6%£¬Ç°°ëÆÚÓëÐ˷ܺóÐË·ÜÐԱ仯ÖÜÆÚÖеÄÏà¶Ô²»Ó¦ÆÚÏ൱£¬Æä»úÖÆ¸ú¼ØÀë×ÓµÄÍâÁ÷Óйء£
9¡¢ intrapulmonary pressure (2013)
·ÎÄÚѹÊÇÖ¸·ÎÅÝÄÚµÄѹÁ¦£¬·ÎÄÚѹÊÇÔÚ²»Í£µÄ¸Ä±äµÄ¡£ºôÆøÊ±£¬·ÎÄÚѹ>´óÆøÑ¹£»ºôÆøÄ©£¬·ÎÄÚѹ=´óÆøÑ¹£»ÎüÆøÊ±£¬·ÎÄÚѹ<´óÆøÑ¹£»ÎüÆøÄ©£¬·ÎÄÚѹ=´óÆøÑ¹¡£
10¡¢ chemical digestion
ÊÇÖ¸Ïû»¯ÏÙ·ÖÃÚµÄÏû»¯Òº¶ÔʳÎï½øÐл¯Ñ§·Ö½â£¬ÓÉÏû»¯ÏÙËù·ÖÃÚ¸÷ÖÖÏû»¯Ã¸£¬½«¸´Ôӵĸ÷ÖÖÓªÑøÎïÖÊ·Ö½âΪ³¦±Ú¿ÉÒÔÎüÊյļòµ¥µÄ»¯ºÏÎÈçÌÇÀà·Ö½âΪµ¥ÌÇ£¬µ°°×ÖÊ·Ö½âΪ°±»ùËᣬ֬Àà·Ö½âΪ¸ÊÓͼ°Ö¬·¾Ëá¡£
11¡¢ afferent collateral inhibition (2013)
³å¶¯ÑØÒ»¸ù¸Ð¾õ´«ÈëÏËά½øÈëÖÐÊàºó£¬³ýÖ±½ÓÐË·ÜijһÖÐÊàµÄÉñ¾ÔªÍ⣬»¹·¢³ö²àÖ§ÐË·ÜÁíÒ»ÒÖÖÆÐÔÖмäÉñ¾ÔªµÄ»î¶¯£¬×ª¶øÒÖÖÆÁíÒ»ÖÐÊàÉñ¾Ôª£¬ÕâÖÖÏÖÏó³ÆÎª´«Èë²àÖ§ÐÔÒÖÖÆ£¨Óֳƽ»»¥ÐÔÒÖÖÆ£©¡£
12¡¢ all-or-none (2012)
ϸ°û²úÉú¶¯×÷µçλµÄÌØµãÊÇ£¬µ±´Ì¼¤Ç¿¶ÈСÓÚãд̼¤Ê±£¬Ï¸°û²»²úÉú¶¯×÷µç룬µ±´Ì¼¤Ç¿¶ÈµÈÓÚ»ò´óÓÚãÐÇ¿¶Èʱ£¬Ï¸°û¼´²úÉú¶¯×÷µç룬ÇÒ·ù¶È²»ÔټӴ󣬴ËÖÖÏÖÏó³ÆÎª“È«»òÎÞ”¡£¼´¶¯×÷µçλµÄ´óС²»Ëæ´Ì¼¤Ç¿¶ÈµÄ¸Ä±ä¶ø¸Ä±ä¡£
13¡¢ recurrent inhibition (2012)
ÊÇָijһÖÐÊàµÄÉñ¾ÔªÐË·Üʱ£¬Æä´«³ö³å¶¯ÑØÖáÍ»Íâ´«£¬Í¬Ê±ÓÖ¾ÖáÍ»²àÖ§È¥ÐË·ÜÁíÒ»ÒÖÖÆÐÔÖмäÉñ¾Ôª£¬¸ÃÒÖÖÆÐÔÉñ¾ÔªÐË·Üºó£¬Æä»î¶¯¾ÖáÍ»·´¹ýÀ´×÷ÓÃÓÚͬһÖÐÊàµÄÉñ¾Ôª£¬ÒÖÖÆÔÏÈ·¢¶¯Ð˷ܵÄÉñ¾Ôª¼°Í¬Ò»ÖÐÊàµÄÆäËûÉñ¾Ôª¡£
14¡¢ overdrive suppression (2012)
µ±×ÔÂÉϸ°ûÔÚÊܵ½¸ßÓÚÆä¹ÌÓÐÆµÂʵĴ̼¤Ê±£¬¾Í°´Íâ¼Ó´Ì¼¤µÄƵÂÊ·¢ÉúÐË·Ü£¬³ÆÎª³¬ËÙÇý¶¯¡£ÔÚÍâÀ´µÄ³¬ËÙÇý¶¯Í£Ö¹ºó£¬×ÔÂÉϸ°û²»ÄܳÊÏÖÆä¹ÌÓеÄ×ÔÂÉÐԻ£¬Ðè¾Ò»¶Î¾²Ö¹ÆÚºó²ÅÖð½¥»Ö¸´Æä×ÔÂÉÐÔ£¬ÕâÖÖÏÖÏó³ÆÎª³¬ËÙÇý¶¯Ñ¹ÒÖ¡£
15¡¢ renal threshold for glucose (2012£¬2016)
ÄòÖв»³öÏÖÆÏÌÑÌǵÄ×î¸ßѪÌÇŨ¶È¡£
OR£º½ü¶ËС¹Ü¶ÔÆÏÌÑÌǵÄÎüÊÕÓÐÒ»¶¨ÏÞ¶È¡£µ±ÑªÌÇŨ¶È´ï180mg/100mlʱ£¬ÓÐÒ»²¿·ÖÉöС¹Ü¶ÔÆÏÌÑÌǵÄÎüÊÕÒѴKÏÞ£¬ÄòÖпªÊ¼³öÏÖÆÏÌÑÌÇ£¬´ËʱµÄѪ½¬ÆÏÌÑÌÇŨ¶È³ÆÎªÉöÌÇãС£
16¡¢ transducer function of receptor (2012)
¸÷ÖÖ¸ÐÊÜÆ÷ÔÚ¹¦ÄÜÉϵÄÒ»¸ö¹²Í¬Ìص㣬ÊÇÄܰÑ×÷ÓÃÓÚËüÃǵĸ÷ÖÖÐÎʽµÄ´Ì¼¤ÄÜÁ¿×ª»»Îª´«ÈëÉñ¾µÄ¶¯×÷µç룬ÕâÖÖÄÜÁ¿×ª»»³ÆÎª¸ÐÊÜÆ÷µÄ»»ÄÜ×÷Óá£
17¡¢ basic electrical rhythm (2011£¬2010£¬2006)
ָθ³¦Æ½»¬¼¡Ï¸°ûÔÚ¾²Ï¢µçλ»ù´¡ÉϲúÉú»ºÂýµÄ½ÚÂÉÐÔµÄ×Ô¶¯È¥¼«»¯²¨£¬ÓÖ³ÆÂý²¨¡£
18¡¢ local potential (2011£¬2009£¬2007£¬2006)
ãÐÏ´̼¤×÷ÓÃÓÚϸ°û£¬ÒýÆðĤÔÓеĵõ½µçλ·¢ÉúÇá΢µÄ¸Ä±ä£¬³ÆÎª¾Ö²¿µçλ¡£
19¡¢ atrioventricular delay (2011£¬2014)
·¿ÊÒ½»½çÇø´«µ¼ËÙ¶È»ºÂý£¬Òò´ËÐË·ÜÓÉÐÄ·¿´«ÖÁÐÄÊÒÒª¾¹ýÒ»¶ÎÑӸ飬Õâ¸öÏÖÏó³ÆÎª·¿ÊÒÑӸ顣ÕâÒ»ÑÓ¸éʹÐÄÊÒµÄÊÕËõ±Ø¶¨·¢ÉúÔÚÐÄ·¿ÊÕËõÍê±ÏÖ®ºó£¬¶ÔÓÚÐÄÊҵijäÓ¯ºÍÉäѪÊÇÊ®·ÖÖØÒªµÄ¡£
20¡¢ glomerular filtrateion rate (2011£¬2014£¬2015)
µ¥Î»Ê±¼äÄÚ£¨Ã¿·ÖÖÓ£©Á½²àÉöÔàÉú³ÉµÄÔÄòÁ¿¡£
21¡¢ evoked cortical potential (2011)
Ôڸоõ´«Èë³å¶¯µÄ´Ì¼¤Ï£¬´óÄÔÆ¤²ãÄ³Ò»ÇøÓò²úÉú½ÏΪ¾ÖÏ޵ĵçλ±ä»¯£¬³ÆÎªÆ¤²ãÓÕ·¢µçλ¡£
22¡¢ fluid mosaic model (2010)
ϸ°ûĤµÄ¹²Í¬½á¹¹ÌصãÊÇÒÔҺ̬µÄÖ¬ÖÊË«·Ö×Ó²ãΪ»ù¼Ü£¬ÆäÖÐÏâǶמßÓв»Í¬ÉúÀí¹¦Äܵĵ°°×ÖÊ¡£
23¡¢ thrombosis (2010)
ÔÚ»îÌåµÄÐÄÔà»òѪ¹ÜÇ»ÄÚ£¬ÑªÒº·¢ÉúÄý¹Ì»òѪҺÖеÄijЩÓÐÐγɷֻ¥ÏàÕ³¼¯£¬ÐγɹÌÌåÖÊ¿éµÄ¹ý³Ì£¬³ÆÎªÑªË¨Ðγɡ£
24¡¢ inward rectifier (2010)
ÄÚÈëÐÔÕûÁ÷ÊÇÖ¸ÕýÀë×ÓÒ×´Óϸ°ûĤÍâÁ÷ÈëĤÄÚ,¶ø²»Ò×´Óϸ°ûĤÄÚÁ÷ÈëĤÍâ¡£
25¡¢ amyloidosis (2010)
ÊÇÖ¸Ò»×é¾ùÔÈÎ޽ṹ¡¢³ÊÌØÊâȾɫ·´Ó¦µÄµí·ÛÑùµ°°×ÖʳÁ»ýÓÚ×éÖ¯»òÆ÷¹Ù£¬µ¼ÖÂÏàÓ¦×éÖ¯Æ÷¹Ù·¢Éú²»Í¬³Ì¶ÈµÄÐÎ̬¸Ä±äºÍ¹¦ÄÜÕϰµÄ¼²»¼¡£
26¡¢ infarction (2010)
Æ÷¹Ù»ò¾Ö²¿×éÖ¯ÓÉÓÚѪ¹Ü×èÈû¡¢ÑªÁ÷Í£Ö¹µ¼ÖÂȱÑõ¶ø·¢ÉúµÄ»µËÀ£¬³ÆÎª¹£ËÀ¡£
27¡¢ migrating motility complex, MMC (2010)
¿Õ¸¹Ê±£¬Î¸³¦Ô˶¯³ÊÏÖÒÔ¼äЪÐÔÇ¿Á¦ÊÕËõ²¢°éÓнϳ¤¾²Ï¢ÆÚÎªÌØÕ÷µÄÖÜÆÚÐÔÔ˶¯£¬¿É½«Î¸³¦µÀÄÚ²ÐÁôÎïÇå³ý¸É¾»£¬Æð“ÇåµÀ·ò”µÄ×÷Óá£
28¡¢ emergency reaction (2010£¬2008)
µ±»úÌåÄÚÍâ»·¾³¾çÁұ仯ʱ£¬°üÀ¨´´ÉË¡¢È±Ñõ¡¢¸ÐȾ¡¢¾çÍ´¡¢ÊÖÊõ¡¢¼¢¶ö¡¢º®Àä¡¢½¹ÂÇ¡¢½ôÕÅη¾åµÈ£¬Õâһϵͳ½«Á¢¼´µ÷¶¯ÆðÀ´£¬ÉöÉÏÏÙËèÖʼ¤ËØ£¨È¥¼×ÉöÉÏÏÙËØ¡¢ÉöÉÏÏÙËØ£©µÄ·ÖÃÚÁ¿´ó´óÔö¼Ó£¬·¢ÉúһϵÁÐÊÊÓ¦ÐÔ·´Ó¦£¬³ÆÖ®ÎªÓ¦¼±·´Ó¦¡£
29¡¢ referred pain (2010£¬2009£¬2008£¬2006)
ijЩÄÚÔ༲²¡ÍùÍùÒýÆðÉíÌåÔ¶¸ôµÄÌå±í²¿Î»·¢ÉúÌÛÍ´»òÍ´¾õ¹ýÃô£¬ÕâÖÖÏÖÏó³ÆÎªÇ£ÉæÍ´¡£
30¡¢ functional residual capacity (2010)
ƽ¾²ºôÆøÄ©ÉдæÁôÓÚ·ÎÄ򵀮øÁ¿³ÆÎª¹¦ÄÜ²ÐÆøÁ¿£¬ÊÇ²ÐÆøÁ¿ºÍ²¹ºôÆøÁ¿Ö®ºÍ¡£
31¡¢ pulmonary surfactant (2009Ãû½â£¬2012¡¢2011¼ò´ð)
ÊǸ´ÔÓµÄÖ¬µ°°×»ìºÏÎÖ÷Òª³É·ÖÊǶþÈíÖ¬õ£ÂÑÁ×Ö¬ºÍ±íÃæ»îÐÔÎïÖʽáºÏµ°°×£¬Ç°ÕßÔ¼Õ¼60%ÒÔÉÏ£¬ºóÕßÔ¼Õ¼10%¡£·Î±íÃæ»îÐÔÎïÖÊÖ÷ÒªÓÉ·ÎÅÝIIÐÍϸ°ûºÏ³É²¢ÊÍ·Å£¬Æä×÷ÓÃÊǽµµÍ·ÎÅݱíÃæÕÅÁ¦¡£ÉúÀíÒâÒåÊÇ£º¢Ùά³Ö·ÎÅݵÄÎȶ¨ÐÔ£»¢Ú·ÀÖ¹·ÎË®Ö×£»¢Û½µµÍÎüÆø×èÁ¦£¬¼õÉÙÎüÆø×ö¹¦¡£
32¡¢ receptive relaxation (2009£¬2007)
½øÊ³Ê±£¬Ê³Îï´Ì¼¤ÑÊ¡¢Ê³¹ÜµÈ´¦¸ÐÊÜÆ÷£¬·´ÉäÐÔµØÒýÆðθµ×ºÍθÌ岿¼¡ÈâÊæÕÅ£¬³ÆÎªÈÝÊÜÐÔÊæÕÅ¡£
33¡¢ resting potential (2009)
ϸ°ûÔÚ°²¾²×´Ì¬Ï´æÔÚÓÚĤÄÚÍâÁ½²àµÄµçλ²î£¬³ÆÎª¾²Ï¢µçλ¡£
34¡¢ filtration fraction (2015£¬2009£¬2006)
ÉöСÇòÂ˹ýÂʺÍÉöѪÁ÷Á¿µÄ±ÈÖµ³ÆÎªÂ˹ý·ÖÊý¡£
35¡¢ myocardial contractility/ inotropic state (2009£¬2006)
Ð»ÒÀÀµÓÚǰ¸ººÉºÍºó¸ººÉ¶øÄܸıäÆäÁ¦Ñ§»î¶¯£¨°üÀ¨ÊÕËõµÄÇ¿¶ÈºÍËÙ¶È£©µÄÄÚÔÚÌØÐÔ£¬³ÆÎªÐļ¡ÊÕËõÄÜÁ¦£¬ÓÖ³ÆÐıäÁ¦×´Ì¬¡£
36¡¢ ventilation/ perfusion ratio (2009£¬2008£¬2006)
ÊÇָÿ·Ö·ÎÅÝÍ¨ÆøÁ¿£¨VA£©ºÍÿ·Ö·ÎѪÁ÷Á¿£¨Q£©Ö®¼äµÄ±ÈÖµ£¨VA /Q£©£¬Õý³£³ÉÄêÈ˰²¾²Ê±Ô¼Îª4.2/5=0.84¡£
37¡¢ glomerulotubular balance (2009£¬2006)
²»ÂÛÉöСÇòÂ˹ýÂÊÔö¼Ó»ò¼õÉÙ£¬½ü¶ËС¹ÜµÄÖØÎüÊÕÂÊʼÖÕÕ¼ÉöСÇòÂ˹ýÂʵÄ65%-70%£¬ÕâÖÖÏÖÏó³ÆÎªÇò¹Üƽºâ¡£
38¡¢ spinal shock (2009£¬2008)
È˺Ͷ¯ÎïÔÚ¼¹ËèÓë¸ßλÖÐÊàÖ®¼äÀë¶Ïºó·´Éä»î¶¯ÄÜÁ¦ÔÝʱɥʧ¶ø½øÈëÎÞ·´Ó¦×´Ì¬µÄÏÖÏó³ÆÎª¼¹Ðݿˡ£
39¡¢ stretch reflex (2009£¬2006£¬2010£¬2015)
ÊÇÖ¸¹Ç÷À¼¡Êܵ½ÍâÁ¦Ç£ÀʱÒýÆðÊÜÇ£ÀµÄͬһ¼¡ÈâÊÕËõµÄ·´Éä»î¶¯¡£
40¡¢ aldosterone (2009)
ÓÉÉöÉÏÏÙÆ¤ÖÊÇò×´´øÏ¸°ûºÏ³ÉºÍ·ÖÃÚµÄÒ»ÖÖÑÎÆ¤Öʼ¤ËØ¡£Ö÷Òª×÷ÓÃÓÚÉöÔàÔ¶ÇúС¹ÜºÍÉöƤÖʼ¯ºÏ¹Ü£¬Ôö¼Ó¶ÔÄÆÀë×ÓµÄÖØÎüÊպʹٽø¼ØÀë×ÓµÄÅÅй£¬Ò²×÷ÓÃÓÚËèÖʼ¯ºÏ¹Ü£¬´Ù½øÇâÀë×ÓµÄÅÅй£¬ËữÄòÒº¡£
41¡¢ permissive action (2009£¬2008£¬2007)
ij¼¤ËضÔÌØ¶¨Æ÷¹Ù¡¢×éÖ¯»òϸ°ûûÓÐÖ±½Ó×÷Ó㬵«ËüµÄ´æÔÚÈ´ÊÇÁíÒ»ÖÖ¼¤ËØ·¢»ÓÉúÎïЧӦµÄ±ØÒª»ù´¡£¬Õâ³ÆÎªÔÊÐí×÷Óá£
42¡¢ isometric contraction (2008£¬2014)
¼¡ÈâÊÕËõʱֻÓÐÕÅÁ¦µÄÔö¼Ó¶øÎÞ³¤¶ÈµÄËõ¶Ì£¬³ÆÎªµÈ³¤ÊÕËõ¡£
43¡¢ hematocrit (2008)
Ѫϸ°ûÔÚѪҺÖÐËùÕ¼µÄÈÝ»ý°Ù·Ö±È³ÆÎªÑªÏ¸°û±ÈÈÝ¡£Õý³£³ÉÄêÄÐÐÔµÄѪϸ°û±ÈÈÝΪ40%-50%£¬³ÉÄêÅ®ÐÔΪ37%-48%¡£
44¡¢ gastric emptying (2008)
ָʳÃÓÓÉθÅÅÈëÊ®¶þÖ¸³¦µÄ¹ý³Ì¡£
45¡¢ exocytosis (2008)
ÊÇÖ¸°ûÖÊÄڵĴó·Ö×ÓÎïÖÊÒÔ·ÖÃÚÄÒÅݵÄÐÎʽÅųöϸ°ûµÄ¹ý³Ì¡£
46¡¢ cardiac cycle (2008)
ÐÄÔàÒ»´ÎÊÕËõºÍÊæÕÅ£¬¹¹³ÉÒ»¸ö»úе»î¶¯ÖÜÆÚ£¬³ÆÎªÐ͝ÖÜÆÚ¡£
47¡¢ EPSP (2007)
Í»´¥ºóĤÔÚµÝÖÊ×÷ÓÃÏ·¢ÉúÈ¥¼«»¯£¬Ê¹¸ÃÍ»´¥ºóÉñ¾ÔªµÄÐË·ÜÐÔÉý¸ß£¬´ËÖÖµçλ±ä»¯³ÆÎªÐË·ÜÐÔÍ»´¥ºóµçλ¡£
48¡¢ decerebrate rigidity (2007)
ÔÚÖÐÄÔÉÏ¡¢ÏÂÇðÖ®¼äÇжÏÄԸɺ󣬶¯Îï³öÏÖÉ켡£¨¿¹ÖØÁ¦¼¡£©µÄ½ôÕÅÐÔ¿º½ø£¬±íÏÖΪËÄÖ«ÉìÖ±£¬¼áÓ²ÈçÖù£¬Í·Î²°ºÆð£¬¼¹ÖùͦӲ£¬ÕâÒ»ÏÖÏó³ÆÎªÈ¥´óÄÔ½©Ö±¡£
49¡¢ ascending reticular activating system (2007)

